GEN Exclusives

More »

GEN News Highlights

More »
Sep 28, 2012

EC Clears Dacogen for AML in the Over-65s

  • Astex and partner Janssen-Cilag International reported EC approval for Dacogen™ (decitabine) for the treatment of adults aged 65 years and over with newly diagnosed de novo or secondary acute myeloid leukemia (AML). The DNA hypomethylating drug is already approved for treating myelodysplastic syndromes (MDS) in over 35 countries, including the U.S.

    EC clearance for the AML indication was based on results from the Phase III Dacoo-016 study, which compared treatment using either decitabine infusions, supportive care, or low-dose cytarabine in 485 subjects aged 65 years and over. An analysis of protocol-specified results showed that decitabine therapy was associated with a 54% increase in median overall survival (7.7 months for decitabine-treated patients, compared with 5.0 months in the comparator arm). Subsequent analysis of mature survival data confirmed the trend for overall survival and provided clinically significant evidence of decitabine efficacy.

    “Dacogene nicely complements our growing portfolio of therapies to treat hematologic malignancies, which is one of our key areas of focus in oncology,” comments Peter Lebowitz, M.D., oncology therapeutic area head for Janssen R&D.

    Astex Pharmaceuticals co-developed Dacogen and receives significant royalties on global sales from Eisai in North America and from Janssen-Cilag in the rest of the world. Under terms of its licensing deals the firm may receive up to $17.5 million in future payments if milestones are achieved for Dacogen globally.

Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

The Triple Package and Success

One theory for explaining “success," put forward by Amy Chua Jed Rubenfeld, posits cultural traits such as a superiority complex, personal insecurity and impulse control. Union College professors Joshua Hart and Christopher Chabris counter that intelligence, conscientiousness, and economic advantage are the most likely elements of success, regardless of ethnicity. Do you think that Hart-Chabris make a better argument for achieving success than the Chua-Rubenfeld theory?

More »